{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"32"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"9"}],"units":"Participants"}],"description":"Percentage of patients whose best overall response to treatment was complete response or partial response (as assessed by Response Evaluation Criteria in Solid Tumours guideline version 1.1)","groups":[{"description":"0.1 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks","id":"OG000","title":"CTX-471 Monotherapy 0.1 mg/kg"},{"description":"0.3 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks","id":"OG001","title":"CTX-471 Monotherapy 0.3 mg/kg"},{"description":"0.6 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks","id":"OG002","title":"CTX-471 Monotherapy 0.6 mg/kg"},{"description":"1.2 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks","id":"OG003","title":"CTX-471 Monotherapy 1.2 mg/kg"},{"description":"0.1 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks + 400 mg of pembrolizumab by IV infusion over 30 minutes every 6 weeks","id":"OG004","title":"CTX-471 Combination 0.1 mg/kg"},{"description":"0.3 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks + 400 mg of pembrolizumab by IV infusion over 30 minutes every 6 weeks","id":"OG005","title":"CTX-471 Combination 0.3 mg/kg"},{"description":"0.6 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks + 400 mg of pembrolizumab by IV infusion over 30 minutes every 6 weeks","id":"OG006","title":"CTX-471 Combination 0.6 mg/kg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Response Evaluable Analysis Set: all patients with measurable disease before treatment who received CTX-471 (and pembrolizumab in combination arms) and had at least 1 post-treatment response assessment or discontinued treatment due to progression of disease progression within 8 weeks after first dose of study treatment","reportingStatus":"POSTED","timeFrame":"From the first dose of CTX-471 to treatment discontinuation (average of 18 weeks for monotherapy groups and and average of 15 weeks for combination groups)","title":"Overall Response Rate","type":"SECONDARY","unitOfMeasure":"Participants"}